Vanguard Group
IMVT icon

Vanguard Group’s Immunovant IMVT Stock Holding History

Vanguard Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$198M Buy
7,779,314
+952,504
+14% +$21.2M ﹤0.01% 1551
2025
Q3 		$110M Sell
6,826,810
-199,128
-3% -$3.22M ﹤0.01% 1817
2025
Q2 		$112M Buy
7,025,938
+89,079
+1% +$1.35M ﹤0.01% 1780
2025
Q1 		$119M Buy
6,936,859
+257,445
+4% +$5.39M ﹤0.01% 1720
2024
Q4 		$165M Buy
6,679,414
+20,614
+0.3% +$585K ﹤0.01% 1632
2024
Q3 		$190M Buy
6,658,800
+149,047
+2% +$4.4M ﹤0.01% 1568
2024
Q2 		$172M Buy
6,509,753
+31,449
+0.5% +$895K ﹤0.01% 1569
2024
Q1 		$209M Buy
6,478,304
+650,506
+11% +$23.7M ﹤0.01% 1490
2023
Q4 		$246M Sell
5,827,798
-405,348
-7% -$14.9M 0.01% 1387
2023
Q3 		$239M Buy
6,233,146
+764,530
+14% +$17.3M 0.01% 1339
2023
Q2 		$104M Buy
5,468,616
+324,907
+6% +$6.06M ﹤0.01% 1829
2023
Q1 		$79.8M Buy
5,143,709
+74,590
+1% +$1.29M ﹤0.01% 1933
2022
Q4 		$90M Buy
5,069,119
+1,068,669
+27% +$13.5M ﹤0.01% 1862
2022
Q3 		$22.3M Buy
4,000,450
+957
+0% +$4.68K ﹤0.01% 2585
2022
Q2 		$15.6M Buy
3,999,493
+233,780
+6% +$1.01M ﹤0.01% 2771
2022
Q1 		$20.8M Sell
3,765,713
-68,406
-2% -$426K ﹤0.01% 2754
2021
Q4 		$32.7M Buy
3,834,119
+84,833
+2% +$700K ﹤0.01% 2581
2021
Q3 		$32.6M Sell
3,749,286
-251,411
-6% -$2.27M ﹤0.01% 2605
2021
Q2 		$42.3M Buy
4,000,697
+3,977
+0.1% +$55.5K ﹤0.01% 2459
2021
Q1 		$64.1M Buy
3,996,720
+118,171
+3% +$3.12M ﹤0.01% 2174
2020
Q4 		$179M Buy
3,878,549
+697,905
+22% +$32.3M 0.01% 1525
2020
Q3 		$112M Buy
3,180,644
+1,490,530
+88% +$44.8M ﹤0.01% 1635
2020
Q2 		$41.2M Buy
+1,690,114
New +$36.2M ﹤0.01% 2096

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group's IMVT Position: Q4 2025 in Review

Vanguard Group increased its Immunovant (IMVT) stake by 14% in Q4 2025, buying an estimated $21.2M and bringing the position to 7,779,314 shares worth $198M. The position accounts for ﹤0.01% of the portfolio, ranked #1551.

Vanguard Group first reported a position in IMVT in Q2 2020 and has held it in 23 quarters since. The position peaked at $246M in Q4 2023. 196 funds tracked by Wall St. Rank hold IMVT as of Q4 2025.

  • Vanguard Group held 7,779,314 shares of Immunovant worth $198M as of Q4 2025.
  • Vanguard Group bought 952,504 Immunovant shares in Q4 2025, an estimated $21.2M.
  • Immunovant made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1551 holding.
  • Vanguard Group first reported a position in Immunovant in Q2 2020 and has held it in 23 quarters since.
  • Vanguard Group's Immunovant position peaked at $246M in Q4 2023.
  • 196 funds tracked by Wall St. Rank held Immunovant as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.